A stem-cell therapy carried out in the allogeneic setting, standing for one donor-many recipients, enables the manufacture of a batch of the medicine from its starting material obtained from one properly evaluated donor and with no necessity for every-time acquisition of biological material from a given patient in order to obtain their own cells for the purposes of this therapy. „The manufacturing technology of stem cell-based biopharmaceuticals developed will facilitate their off‑the-shelf and on-site (in a veterinary clinic) availability”, says Łukasz Bzdzion, the President of the Management Board of Bioceltix: a company working on innovative therapies in veterinary medicine by using immunomodulatory properties of mesenchymal stem cells (MSC). More information on the most advanced therapies for animals can be found on weterynarianews.pl.
